New Delhi. The All India Organisation of Chemists and Druggists (AIOCD) has submitted a consolidated representation to the Chairman and Secretary of the Drug Technical Advisory Board (DTAB) regarding key agenda items (2, 5, 7, 9, and 12) discussed in the 93rd DTAB meeting held on 16th February 2026.
AIOCD President J. S. Shinde and General Secretary Rajiv Singhal reaffirmed their commitment to public health, the rational use of medicines, and the protection of the regulated drug distribution system. They also expressed serious concern over the growing menace of illegal and unregulated e-pharmacies, which pose significant risks to patient safety and undermine licensed brick-and-mortar chemists.
Key Highlights of AIOCD’s Representation
Agenda 2 (Good Distribution Practices – GDP): AIOCD has welcomed the proposal, subject to phased and practical implementation after taking all stakeholders into confidence and ensuring no undue burden on small and medium traders.
Agenda 5 (Advertisement of Schedule H, H1 & X Drugs): Strong opposition has been raised, citing risks of self-medication, misuse, and commercialization of prescription drugs. AIOCD has urged continuation of the existing prohibition without dilution.
Agenda 7 (Amendment in Rule 64 – Competent Person): The proposed changes have been opposed as impractical and burdensome, especially for MSME wholesalers, with potential disruption to the supply chain.
Agenda 9 (Schedule K Exemption for Nicotine Gum 2 mg): AIOCD has strongly objected due to the addictive nature of nicotine and risks of misuse, recommending that such products remain under licensed chemist supervision.
Agenda 12 (Stocking of Homoeopathic Medicines): The proposal has been welcomed, with suggestions for maintaining proper records and avoiding additional compliance burden. However, AIOCD has cautioned against misuse by illegal e-pharmacies.
Serious Concern
AIOCD has reiterated the urgent need for strict enforcement against illegal e-pharmacies operating without valid licenses. It has also urged the immediate withdrawal of draft provisions such as GSR 817 and GSR 220, citing regulatory ambiguity and misuse.
AIOCD has requested DTAB to reject proposals under Agenda 5, 7, and 9, implement Agenda 2 with stakeholder consultation, and expedite Agenda 12 in a balanced manner. The organisation emphasized that public health and regulated drug distribution must remain paramount.